Research to Prevent Blindness


RPB-funded researchers at Washington University School of Medicine in St. Louis (WUSTL) have found a correlation in 30 older patients between retina thinning and elevated levels of tau and amyloid proteins that are the hallmark of Alzheimer’s disease.  They made their discovery by using optical coherence tomography angiography (OCTA) to examine the patients’ retinas. 

This first-of-its-kind research was published in August 23, 2018 in JAMA Ophthalmology.  The study was funded by an RPB Unrestricted Grant to the WUSTL Department of Ophthalmology. 

eye exam to screen for Alzheimer's

Gregory Van Stavern, MD, (seated) and Rajendra Apte, MD, PhD, examine a patient’s eyes, using technology to screen for Alzheimer's disease during an eye exam.


Photo credit: Matt Miller

Participants in the study were patients in The Memory and Aging Project at Washington University’s Knight Alzheimer’s Disease Research Center. About half of those in the study had elevated levels of amyloid or tau as found by PET scans or in cerebrospinal fluid.  This suggests that although they didn’t have symptoms, they likely would develop Alzheimer’s. In the other study subjects, PET scans and cerebrospinal fluid analyses were normal.

Of the patients studied, 17 had abnormal PET scans or lumbar punctures (to test cerebrospinal fluid), and all had retinal thinning and significant areas without blood vessels in the centers of their retinas.  Patients with normal PET scans and lumbar punctures had retinas that appeared normal.  

“In the patients with elevated levels of amyloid or tau, we detected significant thinning in the center of the retina,” said co-principal investigator Rajendra S. Apte, MD, PhD, the Paul A. Cibis Distinguished Professor of Ophthalmology and Visual Sciences. “All of us have a small area devoid of blood vessels in the center of our retinas that is responsible for our most precise vision. We found that this zone lacking blood vessels was significantly enlarged in people with preclinical Alzheimer’s disease.”

The eye test used in the study, which is similar to technology found in many ophthalmologists’ offices, shines light into the eye, allowing the physician to measure retinal thickness, as well as thickness of the fibers in the optic nerve.  In this study, researchers added angiography, which allows physicians to distinguish red blood cells from other tissue in the retina.

Dr. Apte has been a recipient of the RPB Nelson Trust Award for Retinitis Pigmentosa (2016); the RPB Physician Scientist Award (2014); and the RPB Career Development Award (2004).  

While this was a preliminary study, Dr. Apte and colleagues believe that OCTA may become an inexpensive and noninvasive way to determine who should undergo more extensive Alzheimer’s testing.



Related News: Feature Story, For the Media, Top Story

RPB logo
Watch The Video

Research to Prevent Blindness Celebrates 60th Anniversary

For the past 60 years, RPB has funded groundbreaking research to prevent, treat and cure all conditions that damage or destroy sight.

Read More

Letter from NEI

National Eye Institute Recognizes RPB's 60th Anniversary

The NEI congratulates RPB on 60 years of accomplishments in a personal letter from the acting director.

Read More

CDA banner art
Watch The Video

In Their Own Words: Why the RPB Career Development Awards Matter

Thank you to our donors for supporting the RPB CDA and launching more than 200 research careers!

Read More

Dr. Semenza and colleague work in his lab

Research to Prevent Blindness Grantee Dr. Gregg Semenza Wins Nobel Prize in Medicine

Dr. Semenza is being recognized for his discoveries related to how cells respond to low oxygen levels, which have implications for the treatment of cancer, eye diseases and more.

Read More

RPB logo

RPB and Partners Award $1.2 Million In Grants for Novel AMD Research

Four new grantees received the Catalyst Awards for Innovative Research Approaches for AMD.

Read More

CDA 30th Anniversary book

The Career Development Award Turns 30: Celebrating a Generation of Support for Early-Career Scientists

CDA founded 30 years ago as one of the few private sources of funding aimed specifically at early-career vision researchers.

Read More



Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.